| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
BetterNight’s platform integrates a comprehensive sleep apnea solution including screening, testing, telemedicine, therapy and remote patient monitoring. This comprehensive platform is unique in the market providing clients the opportunity to ...
Northwest Kinetics, L.L.C. is a Tacoma, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Corinthian Ophthalmic is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The American Physical Therapy Associations top-ranked private physical therapy practice, and the top-rated physical therapists in New York City.